2023 bio accounting conference, 2023 bio accounting cpe, 2023 cbi accounting, 2023 cbi accounting coe, 2023 deloitte life science cpe, 2023 deloitte pharma cpe, 2023 ernst & young cpe life science, 2023 ey pharma cpe, 2023 kpmg life science, 2023 kpmg pharma cpe, 2023 life science accounting, 2023 life science accounting boston, 2023 life science accounting conference, 2023 life science accounting cpe, 2023 life science accounting seminar, 2023 life science accounting training, 2023 life science leases, 2023 life science revenue recognition, 2023 life science technical accounting, 2023 medical device accounting cpe, 2023 medical device cpe conference, 2023 pharma accounting, 2023 pharma accounting boston, 2023 pharma accounting conference, 2023 pharma accounting cpe. 2023 pharma accounting seminar, 2023 pharma cpe, 2023 pwc life science, cbinet, cbinet 2023, cbinet boston, cbinet pharma 2023
Life Science Technical Accounting Update 2023
VIRTUAL CONFERENCE
From Gross to Net Estimates to IPR&D and intanglible assets to Revenue Recognition examples, M&A Trends, Complex Debt and Equity Structures in Life Sciences, Tax News, ESG, Regulatory Updates, Joint Ventures: Accounting Considerations and latest updates, this conference will address the latest developments in key areas. You’ll hear from experts at Deloitte, Ernst & Young, Effectus Group, life science analysts and your industry counterparts.
LEARNING OBJECTIVES:
- Understand the latest accounting changes in key areas
- Recognize the timelines and key factors affecting the life science industry
- Begin to assess the effects of these standards on your company or clients
REGISTRATION INFORMATION:
Cost: $695
This event will run 8:45-4:40p (Pacific) each day.
Register any one of three ways:
1. Register online using a credit card and click the orange button
2. Register by phone at (610) 789-3110
3. Email your contact info to be invoiced to [email protected]
| Agenda: DAY 1 | ||
|---|---|---|
| 8:45 | 10:10 | Life Science Industry Overview Sector Landscape Miodalities and development pathway Business models and capital formation CFO, accounting and tax lens Regulatory and reinforcement Strategic trends Governance and risk |
| 10:10 | 10:30 | Break |
| 10:30 | 12:00 | Gross to Net & Inventory Accounting Gross to Net Introduction and Overview Industry View Estimation Methodology Approaching Launch Key Challenges SEC Comments Close and Financial Reporting GTN Hot Topics Discussion Inventory Accounting Refresh |
| 12:00 | 12:45 | Lunch Break |
| 1:2:45 | 2:05 | Revenue Recognition for Collaboration & License Agreements Analyze key 606 considerations Understand disclosure expectations Practical approached for estimating and constraining variable consideration Review real-world examples |
| 2:05 | 2:15 | Break |
| 2:15 | 3:30 | GenAI Automation Update What works and what doesn't in corporate accounting Understanding the AI spectrum and AI agents AI in financial reporting & demo Potential impacts to your audit |
| 3:30 | 3:40 | Break |
| 3:40 | 5:00 | Budgeting and Forecasting Best Practices Real life examples of successes and failures Forecast models Leverage different technology approaches |
| Agenda: DAY 2 | ||
|---|---|---|
| 8:45 | 9:55 | Tax Update Latest legislative developments Key Tax Proposals Possible timing and other legislative priorities |
| 9:55 | 10:10 | Break |
| 10:10 | 11:30 | Accounting for Financing Arrangements in Life Sciences |
| 11:30 | 11:45 | Break |
| 11:45 | 1:10 | Accounting for R&D and Clinical Trials R&D Funding Arrangements R&D Cost Classifications Other Intangible Assets SEC Comment Letter Trends |
| 1:10 | 2:00 | Lunch Break |
| 2:00 | 3:15 | SEC & FASB Developments Affecting Life Science Companies Disaggregation of income statement expenses Improvements to income tax disclosures SEC Comment Letter trends FASB developments US regulatory updates PCAOB standard-setting and rulemaking activity |
| 3:15 | 3:30 | Break |
| 3:30 | 4:50 | SOX & Internal Controls Update Use of Gen AI Segment Reporting Control Considerations Risk Assessment refresh Deficiencies and severity assessment |
| Conference Series Speakers Include: |
|---|
| Eugene Bessacini PwC, Deals Director |
| Adam Barrow Riveron, Senior Director |
| Nick Sanfilippo Riveron, Director, Accounting Advisory & IPO |
| Glenn Snyder Riveron, Senior Director - Interim Management |
| Zara Muradali Uncommon Collective, Founder |
| Matt Norman Deloitte, Manager |
| Russ Higgins Connor Group, Partner |
| Travis Combs Riveron, Managing Director |
| Marcus Lindner Ernst & Young, Partner |
| Margaret Smith Protiviti, Managing Director |
| Nathaniel Spedalieri Ernst & Young, Senior Manager |
| Salonee Hanspal Ernst & Young, Assurance Senior Manager |
| Gia Suber Ernst & Young, Senior - Technical Accounting Advisory Group |
| Kyle Straub PwC, Director |
| Moira Klinger PwC, Director |
| Emma Nealis PwC, Manager |
| Aleks Zabreyko Connor Group, Managing Partner |
| Jeffrey Kummer Deloitte, Director of Tax Policy |
| Joshua Areola Ernst & Young, Assurance Senior Manager |
| Tim Geringer Ernst & Young, Senior Manager |
| James Bowie Ernst & Young, Managing Director, Technical Accounting Advisory Group |
| Spencer Moses Ernst & Young, FAAS Manager |
| Tanner Schnitz Ernst & Young, Technical Accounting Manager |
| James Bowie Ernst & Young, Managing Director, Technical Accounting Advisory Group |
| Randa Ghantous Connor Group, Partner |
| Matt Lepley Connor Group, Partner |
| Christie Hutchinson Riveron, Managing Director, Technical Accounting & IPO |
| Alice Chen Ernst & Young, Senior Manager |